<DOC>
	<DOCNO>NCT02333838</DOCNO>
	<brief_summary>Allogeneic cord blood stem cell transplantation potentially curative therapy patient haematological malignancy . We extensive experience use Cord Blood Transplantation ( CBT ) patient advanced myeloid malignancy . In adult however , 40 % Non-Relapse Mortality ( NRM ) rate observe CBT condition myeloablative conditioning encourage development CBT Reduced Intensity Conditioning ( RIC ) . Our previous national CBT protocol ( Minicord French protocol - NCT00797758 ) show RIC CBT reduce NRM , relapse remain main post-transplant event ( &gt; 30 % one year ) . Thus , development reduce toxicity rather RIC condition CBT warrant order improve outcome transplant limit NRM reduce relapse rate . The Fludarabine , ATG intensify dos IV Busulfan ( 9.6 mg/Kg total dose ) regimen well-established preparative regimen reduced-intensity/toxicity conditioning prior allogeneic stem cell transplantation use peripheral blood stem cell mobilize G-CSF ( ClinicalTrials.gov Identifier : NCT00841724 ) . However , regimen likely sufficient allow CB cell engraftment . Thiotepa alkylating radio-mimetic agent large anti-tumor activity include leukemic cell , ability cross blood-brain barrier improve engraftment hematopoietic stem cell . This drug combine usual conditioning regimen without increase toxicity improve engraftment rate potentially reduce relapse rate . Thus , context adult CBT high risk myeloid malignancy , propose prospectively evaluate reduce toxicity condition base association Thiotepa , Fludarabine , IV Busulfan ATG objective achieve acceptable NRM rate , allow improve anti-leukemic control base cytotoxic component condition regimen , wait long term immune-mediated disease control ( GVL effect ) .</brief_summary>
	<brief_title>Reduced Toxicity Conditioning Prior Unrelated Cord Cell Transplantation High Risk Myeloid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients diagnose one follow disease : Acute myelogenous leukemia ( AML ) beyond CR1 CR1 high risk feature ( ≥ intermediate risk 2 ) Myelodysplastic syndromes International Prognostic Scoring System ( IPSS ) score ≥ 2 symptomatic pancytopenia chronic myelomonocytic leukemia ( CMML ) MDS CMML ≤10 % blast transplantation Absence match sibling unrelated donor ( 10/10 9/10 mismatch HLA Cw , base center 's donor selection criterion ) Cord blood unit must match patient 4 , 5 , 6/6 HLA locus , ( class I antigenic &amp; class II allelic level ) minimum 3.5 x 10^7 TNC/kg recipient body weight prethawed fraction ≥2.5x10^7 TNC/kg rich cord blood unit ≥ 1.5x10^7 TNC/kg poor blood unit case 2 cord blood unit Performance status : OMS score ≤ 1 ( cf . appendix 5 ) Cardiac function leave ventricular ejection fraction ≥ 45 % . Pulmonary function diffusion capacity least 50 % predict . Serum creatinine clearance 0 ml/min . SGPT 4x normal , serum bilirubin &lt; 2 x normal . Written informed consent . Progestative treatment woman persist menstrual period Presence match sibling unrelated available donor ( 10/10 9/10 mismatch HLA Cw center perform 9/10 HLA mismatch transplant ) Active infection time conditioning . In case uncertainty regard whether previous infection resolve , discuss PI case case basis . Pregnancy woman child bear potential ( pregnancy test perform within 24 week study entry ) . HIV positive Active CNS leukemia Chronic active Hepatitis B Hepatitis C. If question liver health discus PI strongly consider liver biopsy . Poor performance status : OMS score &gt; 1 Life expectancy severely limited concomitant illness expect &lt; 12 week . Left ventricular ejection fraction &lt; 45 % . Uncontrolled arrhythmias symptomatic cardiac disease . Symptomatic pulmonary disease . FEV1 , FVC DLCO &lt; 50 % expect corrected hemoglobin . Serum creatinine clearance ( Crockoft ) 50 mL/m per 1.73 m² require dialysis Vaccination alive vaccine ( virus bacteria ) &lt; 3 month Fludarabine contraindication Thymoglobuline contraindication Patient guardianship curatorship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cord Cell Transplantation</keyword>
	<keyword>High risk myeloid malignancy</keyword>
</DOC>